Validity of using background leukemia incidence rates with cohort mortality-based potency estimates to calculate excess lifetime risk

Human and Ecological Risk Assessment

Volumn 10, Issue 5, 2004, Pages 923-938

  Jane Teta, M ^a   Tran, Nga L ^a   Mink, Pamela J ^a   Barraj, Leila M ^a  

^a EXPONENT INC   (United States)

Author keywords

Bias; Leukemia; Lifetime risk; Mortality study; Risk assessment

Indexed keywords

EID: 8844241625     PISSN: 10807039     EISSN: None     Source Type: Journal    
DOI: 10.1080/10807030490513900     Document Type: Article

References (23)

1. Beir IV. 1998. Health risks of radon and other internally deposited alpha emitters, pp 131-4. National Academy Press, Washington, DC, USA
2. Bjork J, Albin M, Mauritzson N, et al. 2001. Smoking and acute myeloid leukemia: associations with morphology and karyotypic patterns and evaluation of dose-response relations. Leuk Res 25(10):865-72
3. Curtis RE, Boice JD, Stovall M, et al. 1992. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326:1745-51
4. Delzell E, Sathiakkumar N, and Hovinga M. 1996. A follow up study of synthetic rubber workers. Toxicology 113:169-81
5. Groves FD, Linet MS, and Devesa SS. 1994. Epidemiology of human leukemia. Curr Opin Hematol 1:321-6
6. Health Canada. 2000. Canadian Environmental Protection Act, 1999. Priorities substances list assessment report: 1,3-butadiene
7. IARC (International Agency for Research on Cancer). 2003. Tobacco Smoke and Involuntary Smoking, p 19. In IARC Press Catalogue
8. Linet MS and Cartwright RA. 1996. The leukemias. In: Schottenfeld D and Fraumeni, Jr. JF (eds), Cancer Epidemiology and Prevention, Second Edition, pp 841-92. Oxford University Press, New York, NY, USA
9. Park R, Rice F, Stayner L, et al. 2002. Exposure to crystalline silica, silicosis, and lung disease other than cancer in diatomaceous earth industry workers: a quantitative risk assessment. Occupat Environ Med 1:36-43
10. Petridou E and Trichopoulos D. 2002. Leukemias. In: Adami H-O, Hunter D, and Trichopoulos D (eds), Textbook of Cancer Epidemiology, pp 556-72. Oxford University Press, New York, NY, USA
11. Pogoda JM, Preston-Martin S, Nichols PW, et al. 2002. Smoking and risk of acute myeloid leukemia: results from a Los Angeles County case-control study. Am J Epidemiol 155(6): 546-53
12. Ries LAG, Eisner MP, Kosary CL, et al. (eds). 2003. SEER Cancer Statistics Review, 1975-2000. National Cancer Institute, Bethesda, MD, USA. Available at http://seer.cancer.gov/csr/ 1975_2000
13. Ron E. 1998. Ionizing radiation and cancer risk: evidence from epidemiology. Radiat Res 150(Suppl. 5):S30-S41
14. Sandler DP, Shore DL, Anderson JR, et al. 1993. Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. J Natl Cancer Inst 85(24):1994-2003
15. SEER (Surveillance, Epidemiology, and End Results Program). 2003a. SEER*Stat Database: Incidence-SEER 9 Registries, Nov 2002 Sub (1973-2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch
16. SEER (Surveillance, Epidemiology, and End Results Program). 2003b. SEER*Stat Database: Mortality - All COD, Public-Use With State, Total U.S. (1969-2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Underlying mortality data provided by NCHS (www.cdc.gov/nchs)
17. Stayner L, Smith R, Thun M, et al. 1992. A dose-response analysis and quantitative assessment of lung cancer risk and occupational cadmium exposure. Ann Epidemiol 2:177-94
18. Steenland K, Deddens J, and Piacitelli L. 2001. Risk assessment for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) based on an epidemiologic study. Am J Epidemiol 154:451-8
19. Swerdlow AJ, Douglas AJ, Hudson GV, et al. 1992. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. Brit Med J 304:1137-43
20. Teta MJ, Sielken RL, and Valdez-Flores C. 1999. Ethylene oxide cancer risk assessment based on epidemiologic data: Application of revised regulatory guidelines. Risk Anal 19:1135-55
21. USEPA (US Environmental Protection Agency). 2002. USEPA Health Assessment of 1,3-Butadiene. EPA/600/P-98001F. Office of Research and Development, National Center for Environmental Assessment, Washington, DC, USA
22. USEPA (US Environmental Protection Agency). 2003a. Draft Final Guidelines for Cancer Risk Assessment. EPA/630/P-03/001A NCEA-F-0644A. Risk Assessment Forum, Washington, DC, USA
23. USEPA (US Environmental Protection Agency). 2003b. Supplementary Guidance for Assessing Susceptibility from Early-life Exposure to Carcinogens. EPA/630/R-03/003. Risk Assessment Forum, Washington, DC, USA